Clinical Trials Browser

Pathologic Complete Response

Locally Advanced Rectal Cancer

Gastric Adenocarcinoma

Colonic Neoplasms

Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

Neoplasm Metastasis, Colorectal Neoplasms

Rectal Neoplasms

Resectable Colon Cancer

Biliary Tract Neoplasms

Solid Tumors

Lymphoma, Large B-Cell, Diffuse

Rectal Neoplasms

Advanced Solid Tumour

Adenocarcinoma

Rectal Neoplasms Malignant

Locally Advanced Rectal Cancer (LARC)

Lymphoma, Large B-Cell, Diffuse

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

Colorectal Neoplasms

Pancreatic Neoplasms

HER2-positive Gastric Cancer

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

Colorectal Neoplasms

Advanced Solid Tumor

Stomach Neoplasms

Appendiceal Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Rectal Neoplasms, Stomach Neoplasms

Adenocarcinoma, Carcinoma, Rectal Neoplasms, Colorectal Neoplasms

Locally Advanced Low Rectal Adenocarcinoma

Colorectal Neoplasms

Colorectal Neoplasms

Rectal Neoplasms

Esophageal Neoplasms, Colorectal Neoplasms

Stomach Neoplasms

Pancreatic Cancer Resectable

CLDN18.2-positive Advanced Biliary Tract Cancer

Colonic Neoplasms

Stomach Neoplasms

Biliary Cancer Metastatic

Advanced Small Intestine Cancer

PDAC - Pancreatic Ductal Adenocarcinoma

Bile Duct Neoplasms, Biliary Tract Neoplasms, Cholangiocarcinoma, Klatskin Tumor

Colorectal Neoplasms

Neoplasms, Stomach Neoplasms

Ovarian Neoplasms

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

Adenocarcinoma

Rectal Neoplasms

Colonic Neoplasms

Clinical Trials

MEND-IT II

Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer

SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer

A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer

QLS5132 Combination Therapy in Advanced Solid Tumors

FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer

Clinical Trial of Neoadjuvant mFOLFOX Plus Alvenor for LARC Patients With High YWHAB Expression

Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer

CROCOBIL

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

A Phase III Study of HMPL-760 in Combination With R-GemOx Versus Placebo in Combination With R-GemOx in Relapsed/Refractory DLBCL

A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed by TNT in High-Risk Locally Advanced Rectal Cancer

A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]

Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.

CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer

IMMUNOSTAR

Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma

ARIEL-ENGIC

Chemotherapy With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable or Locally Advanced Pancreatic Cancer

A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer

Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations

A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation

A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors

Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma

Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays

Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer

PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer

FOXHIPECT4

Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)

A Pilot Study Evaluating β-hydroxybutyrate Supplementation Concomitant to Short-Course Radiotherapy Followed by Immunotherapy Combined With CAPEOX Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer

A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers

Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer

LEFT-PANC

Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract Cancer

Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer

Irinotecan Liposome II + 5-FU/LV + Oxaliplatin + Karelizumab in Neoadjuvant Treatment of Gastric Cancer

mFOLFOX/mFOLFIRI vs. mFOLFOX in Advanced or Recurrent Biliary Tract Cancer Second-line

NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers

PANORAMIX

Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma

QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer

YOUNG-NEOS

SHR - A1811 Injection in the Treatment of Platinum-sensitive Recurrent Ovarian Cancer

A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors

Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

A Phase ll Study of Neoadjuvant Short-course Radiotherapy Followed by Ivonescimab and Chemotherapy in pMMR/MSS Locally Advanced Rectal Cancer

Pre-Operative Treatment in REseCTable COlon CanceR